New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
04:55 EDTEXEL, EXEL, EXEL, AGIO, AGIO, AGIO, ALNY, ALNY, ALNY, EPZM, EPZM, EPZM, INFO, INFO, INFO, VRTX, VRTX, VRTX, FMI, FMI, FMIBernstein to hold a conference
Emerging Biotech Conference 2014 is being held in Snowbird, Utah on March 10-12.
News For EXEL;AGIO;ALNY;EPZM;INFO;VRTX;FMI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 2, 2015
07:20 EDTFMICowen to hold a conference
Subscribe for More Information
February 27, 2015
09:58 EDTALNYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:59 EDTALNYAlnylam initiated with an Outperform at Cowen
Subscribe for More Information
February 25, 2015
10:01 EDTFMIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:23 EDTFMIFoundation Medicine downgraded at Wedbush
Subscribe for More Information
07:55 EDTFMIFoundation Medicine price target raised to $60-$65 from $55-$60 at Wells Fargo
Subscribe for More Information
07:18 EDTFMIG Corp to hold annual meeting
Subscribe for More Information
06:56 EDTFMIFoundation Medicine downgraded to Neutral from Outperform at Wedbush
06:14 EDTVRTXPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 24, 2015
16:55 EDTEXELExelixis provides 2015 outlook
Subscribe for More Information
16:54 EDTEXELExelixis reports Q4 EPS (30c), consensus (30c)
Reports Q4 revenue $7.4M, consensus $7.8M.
16:03 EDTFMIFoundation Medicine sees FY15 revenue $105M-$115M, consensus $108.47M
The company expects to report between 43,000 and 47,000 clinical tests in 2015. The company expects operating expenses in the range of $128M-$138M. The company expects to launch a cell-free DNA test in 2015.
16:02 EDTFMIFoundation Medicine reports Q4 EPS (47c), consensus (51c)
Reports Q4 revenue $18.7M, consensus $18.05M.
February 23, 2015
07:22 EDTAGIO, ALNYSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
06:31 EDTFMIFoundation Medicine and H3 Biomedicine announce collaboration
Foundation Medicine announced a multi-year collaboration for the discovery and development of precision medicines in oncology. The collaboration marries Foundation Medicine’s comprehensive genomic knowledgebase of more than 35,000 genomic profiles, FoundationCORE, with H3 Biomedicine’s drug discovery engine and computational biology platform. The approach aims to identify potential drug targets based on the unique genomic dependencies of individual cancers, rapidly accelerate clinical development, and lead to the commercialization of new, safe and effective precision medicines for individuals living with cancer. Under the terms of the agreement, H3 Biomedicine will pay Foundation Medicine a technology access fee for identification of target concepts arising from FoundationCORE and success milestones for selection, validation, clinical progression, and commercialization of products developed from the program. In addition, Foundation Medicine is eligible to receive royalties on sales of any products resulting from the collaboration.
February 19, 2015
10:32 EDTEXELHigh option volume stocks:
Subscribe for More Information
09:12 EDTEXELOn The Fly: Pre-market Movers
Subscribe for More Information
09:09 EDTFMILeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
05:31 EDTEXELExelixis announces acceptance of NDA for Genentech cobimetinib
Subscribe for More Information
February 18, 2015
09:04 EDTVRTXVertex data likely to show lung function improvement, says JMP Securities
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use